CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

CG Oncology, Inc. Common stockNASDAQ: CGON

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to -66.4%

Gross margin was -66.4% in Q3 FY2026, down 71.7 pp from a year earlier. On a trailing-twelve-month basis it was -102.2%, up 3807.7 pp year over year. Over 3 fiscal years it narrowed by 107.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-66.4%+172.8 pp QoQ
Last fiscal yearDec 2025
-15.0%+7093.2 pp YoY
LTMSep 2026
-102.2%+3807.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-71.7 pp——
1 year+7093.2 pp——
3 years-107.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-15.0%
Year-over-year change
+7093.2pp

Gross Margin vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 gross margin of -102.2% is the lowest of the 3 companies compared; the peer median is 93.3%.
  • Its year-over-year change of +3807.7 pp is the highest of 3, against a peer median of +1.0 pp.
  • Over three fiscal years its change of -107.2 pp compares with a peer median of -0.1 pp.
CGON Competitors Peer median
Gross Margin for CGON and competitors
Company Period LTM level YoY 3-year change
IBRXImmunityBio, Inc.LTM Sep 202696.7% +1.9 pp-0.7 pp
URGNUroGen Pharma Ltd.LTM Mar 202689.9% +0.2 pp+0.6 pp
CGONCG Oncology, Inc. Common stockLTM Sep 2026-102.2% +3807.7 pp-107.2 pp
Peer median (excluding CGON) 93.3%+1.0 pp-0.1 pp

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.36M191K204K1.14M4.04M
Cost of Revenue10K15K45.75M82.1M4.65M
Gross Profit10.35M176K(45.55M)(80.96M)(607K)
Gross Margin99.9%92.1%-22327.5%-7108.3%-15.0%
Research & Development18.32M29.03M45.75M82.1M116.64M
Selling, General & Admin4.64M6.39M9.9M33.7M73.53M
Operating Expenses22.95M35.42M9.9M33.7M190.17M
Depreciation & Amortization10K15K17K32K1.45M
EBITDA(12.38M)(35.43M)(48.59M)(88.01M)(159.55M)
EBITDA Margin-119.5%-18548.2%-23818.6%-7726.7%-3949.3%
Operating Income(12.61M)(35.25M)(55.45M)(114.67M)(190.77M)
Operating Margin-121.7%-18453.4%-27180.9%-10067.3%-4722.1%
Interest Income006.9M26.62M29.93M
Interest Expense451K1K000
Other Income / Expenses(233K)(197K)6.84M26.63M29.78M
Income Before Tax(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Pre-Tax Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
Income Tax Expense00000
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Net Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
EPS (Basic)(0.28)(0.66)(1.02)(1.41)(2.08)
EPS (Diluted)(0.28)(0.66)(1.02)(1.41)(2.08)
Weighted Avg Shares66.64M66.64M66.64M62.5M77.3M
Weighted Avg Shares (Diluted)66.64M66.64M66.64M62.5M77.3M

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.